Bionik Laboratories Corp. engages in the provision of rehabilitation and mobility solutions to individuals with neurological disorders. The company is headquartered in Watertown, Massachusetts and currently employs 12 full-time employees. The company went IPO on 2012-06-12. Its product portfolio includes three InMotion Robots for rehabilitation following stroke and other neurological conditions and four products in varying stages of development. The InMotion robots offer patient-adaptive therapy, intended to restore upper-extremity motor control for a range of neurological conditions and recovery stages, including early recovery from acute stroke. InMotion Robots also provide objective evaluation assessments intended to measure and report the patient’s level of motor impairment and progress during therapy. Its solutions include InMotion Therapy, InMotion ARM, InMotion ARM/HAND, InMotion EVAL, InMotion Connect, InMotion for Physical Therapy, and InMotion for Occupational Therapy. InMotion Robotics provides the occupational therapist with a range of useful protocols designed to reduce many types of upper extremity neurological impairments.
Follow-Up Questions
Bionik Laboratories Corp의 CEO는 누구입니까?
Mr. Richard Russo은 2020부터 회사에 합류한 Bionik Laboratories Corp의 President입니다.
BNKL 주식의 가격 성능은 어떻습니까?
BNKL의 현재 가격은 $0이며, 전 거래일에 decreased 0% 하였습니다.
Bionik Laboratories Corp의 주요 사업 주제나 업종은 무엇입니까?
Bionik Laboratories Corp은 Health Care 업종에 속하며, 해당 부문은 Health Care입니다